Valneva (NASDAQ:VALN) Stock Price Up 7.1% – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN)’s stock price rose 7.1% during trading on Thursday . The stock traded as high as $10.40 and last traded at $10.3750. Approximately 13,841 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 13,128 shares. The stock had previously closed at $9.69.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered Valneva from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Stock Performance

The company has a fifty day moving average of $9.25 and a two-hundred day moving average of $9.41. The stock has a market capitalization of $867.99 million, a P/E ratio of -7.00 and a beta of 1.84. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.78 and a quick ratio of 1.36.

Valneva (NASDAQ:VALN) last issued its earnings results on Thursday, November 20th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.31). Valneva had a negative return on equity of 59.44% and a negative net margin of 57.81%.The firm had revenue of $34.01 million during the quarter, compared to analyst estimates of $48.85 million. On average, equities analysts anticipate that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva during the 4th quarter valued at about $44,000. Marex Group plc acquired a new stake in shares of Valneva during the 2nd quarter worth approximately $64,000. VSM Wealth Advisory LLC lifted its holdings in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Valneva during the 3rd quarter valued at approximately $124,000. Finally, Frazier Life Sciences Management L.P. bought a new position in Valneva during the 2nd quarter worth $8,240,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.